SP600125: Difference between revisions

From XenWiki
Jump to navigation Jump to search
imported>Kevin
No edit summary
imported>Kevin
No edit summary
Line 23: Line 23:


==References==
==References==
*[https://pubchem.ncbi.nlm.nih.gov/compound/8515 PubChem]
*[http://www.xenbase.org/literature/article.do?method=display&articleId=48899 Cizelsky et al., 2014]
*[http://www.xenbase.org/literature/article.do?method=display&articleId=48899 Cizelsky et al., 2014]
*[http://www.xenbase.org/literature/article.do?method=display&articleId=46881 Zhang et al., 2013]
*[http://www.xenbase.org/literature/article.do?method=display&articleId=46881 Zhang et al., 2013]

Revision as of 13:50, 2 June 2015

Description

MAPK/JNK inhibitor.

"A novel and selective inhibitor of c-Jun N-terminal kinase (JNK) SP600125 is an anthrapyrazolone inhibitor of JNK that competes with ATP to inhibit the phosphorylation of c-Jun. It prevents the activation of inflammatory genes such as COX-2, IL-2 IFN-γ and TNF-α.8,9 It prevents the activation of JNK after brain ischemia and may be effective in treatment of ischemic stroke.10"

  • -Sigma Product Description
SP600125 structure, photo from Sigma-Aldrich

Genes Affected

mapk8 mapk1

Suppliers

Usage Notes

References


>28 Xenbase articles contain a reference to SP600125 according to textpresso